Reports
Sale
Spinal Cord Injury Market Size, Share, Trends, Forecast: By Injury Type: Complete Spinal Cord Injury, Incomplete Spinal Cord Injury; Treatment Type: Corticosteroid, Surgery, Spinal Traction; By End User: Hospitals, Clinics, Others; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Model; Supplier Landscape; 2024-2032
Spinal Cord Injury Market Outlook
The spinal cord injury market size was valued at USD 7215.83 million in 2023, driven by the increasing incidence of road accidents and increasing treatment enhancements across the 7 major markets. The market size is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032 to achieve a value of USD 11574.5 million by 2032.
Spinal Cord Injury: Introduction
A spinal cord injury is considered, hurt, or damage to any part of the spinal cord. It also can include damage to nerves at the end of the spinal cord, known as the cauda equina. The spinal cord is responsible for sending and receiving signals between the brain and the rest of the body. A spinal cord injury often causes permanent changes in strength, feeling, and other body functions.
Spinal Cord Injury Market Analysis
The market for spinal cord injury is witnessing significant advancements in medical technology and innovative approaches that hold promising potential for restoring spinal cord function and improving the lives of individuals with spinal cord injuries. Techniques like electrical stimulation are emerging as transformative solutions for promoting tissue regrowth.
Along with these technological innovations, research initiatives are contributing to the market growth. For instance, scientists at the University of Sydney have been sponsored by a USD 1.7 million grant from NSW Health to explore a novel treatment for chronic pain associated with spinal cord injuries. This research has been conducted in partnership with the Lambert Initiative for Cannabinoid Therapeutics which focuses on investigating the safety and efficacy of cannabidiol (CBD), a non-intoxicating component of cannabis, in alleviating neuropathic pain in individuals with spinal cord injuries. Such expanded mindsets about researching the full potential of elements such as cannabis exhibit the dedication of researchers towards finding an effective solution for the patients, bolstering the spinal cord injury market growth.
Additionally, studies from the Institute of Psychiatry, Psychology & Neuroscience at King's College London highlight the safety and tolerability of a new drug, KCL-286, designed to activate retinoic acid receptor beta (RARb) in the spine to promote recovery after spinal cord injury. Furthermore, a clinical trial led by a renowned pharmacologist at the University of Houston has also demonstrated the promising effectiveness of the drug Riluzole in improving functionality for people with acute spinal cord injuries if administered within 12 hours post-injury. These advancements underscore a positive trend in the spinal cord injury research and treatment market, with potential new therapies and interventions contributing to the market development. The growing focus on innovative solutions, backed by encouraging results from clinical trials, is likely to drive the spinal cord injury market demand as these developments offer hope for improved outcomes and quality of life for individuals with spinal cord injuries.
Spinal Cord Injury Market Segmentations
Market Breakup by Injury Type
- Complete Spinal Cord Injury
- Incomplete Spinal Cord Injury
Market Breakup by Treatment Type
- Corticosteroid
- Surgery
- Spinal Traction
Market Breakup by End User
- Hospitals
- Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
Spinal Cord Injury Market Overview
The spinal cord injury market demand is driven by a significant patient population, with an estimated 250,000 to 500,000 individuals experiencing spinal cord injuries annually, predominantly attributable to preventable causes like violence and motor vehicle accidents. This high incidence serves as a key driver propelling market growth. Major players in the industry are contributing to advancements through innovative devices for spinal cord injury treatment, fostering increased accessibility and improved patient outcomes. The market is further influenced by a surge in approvals and the development of novel drugs tailored for treating spinal cord injuries. The growing number of clinical trials and research and development activities underscore a commitment to exploring and introducing new therapeutic options, bolstering the spinal cord injury market growth.
Geographically, North America stands at the forefront of the market, driven by the increased adoption of innovative technologies in device development and utilization. Government initiatives in the region, focusing on enhancing emergency care and overall healthcare facilities to ensure prompt treatment for spinal cord injuries, are pivotal factors contributing to the market's progress. As the market witnesses a rise in technological innovations, drug approvals, and research endeavors, it is expected to experience substantial growth, offering hope for enhanced treatment options and improved quality of life for those affected by spinal cord injuries.
Spinal Cord Injury Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- Tenax Therapeutics
- Accure Pharma
- Acorda Therapeutics
- Asterias Biotherapeutics
- ReNetX Bio.
- BioArctic AB
- BioTime, Inc
- InVivo Therapeutics
- Kringle Pharma
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Injury Type |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Spinal Cord Injury Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Spinal Cord Injury Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Spinal Cord Injury Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Spinal Cord Injury Epidemiology Forecast (2017-2032)
5.3.1 Germany Spinal Cord Injury Epidemiology Forecast (2017-2032)
5.3.2 France Spinal Cord Injury Epidemiology Forecast (2017-2032)
5.3.3 Italy Spinal Cord Injury Epidemiology Forecast (2017-2032)
5.3.4 Spain Spinal Cord Injury Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Spinal Cord Injury Epidemiology Forecast (2017-2032)
5.4 Japan Spinal Cord Injury Epidemiology Forecast (2017-2032)
6 Spinal Cord Injury Market Overview – 7MM
6.1 Spinal Cord Injury Market Historical Value (2017-2023)
6.2 Spinal Cord Injury Market Forecast Value (2024-2032)
7 Spinal Cord Injury Market Landscape – 7MM
7.1 Spinal Cord Injury Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Spinal Cord Injury Product Landscape
7.2.1 Analysis by Diseases Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
8 Spinal Cord Injury Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Spinal Cord Injury Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Spinal Cord Injury Market Segmentation – 7MM
11.1 Spinal Cord Injury Market by Injury Type
11.1.1 Market Overview
11.1.2 Complete Spinal Cord Injury
11.1.3 Incomplete Spinal Cord Injury
11.2 Spinal Cord Injury Market by Treatment Type
11.2.1 Market Overview
11.2.2 Corticosteroid
11.2.3 Surgery
11.2.4 Spinal Traction
11.3 Spinal Cord Injury Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Clinics
11.3.4 Others
11.4 Spinal Cord Injury Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.4 Japan
12 United States Spinal Cord Injury Market
12.1 Spinal Cord Injury Market Historical Value (2017-2023)
12.2 Spinal Cord Injury Market Forecast Value (2024-2032)
12.3 Spinal Cord Injury Market by Disease Type
12.4 Spinal Cord Injury Market by Treatment Type
13 EU-4 and United Kingdom Spinal Cord Injury Market
13.1 Spinal Cord Injury Market Historical Value (2017-2023)
13.2 Spinal Cord Injury Market Forecast Value (2024-2032)
13.3 Germany Spinal Cord Injury Market Overview
13.3.1 Spinal Cord Injury Market by Disease Type
13.3.2 Spinal Cord Injury Market by Treatment Type
13.4 France Spinal Cord Injury Market Overview
13.4.1 Spinal Cord Injury Market by Disease Type
13.4.2 Spinal Cord Injury Market by Treatment Type
13.5 Italy Spinal Cord Injury Market Overview
13.5.1 Spinal Cord Injury Market by Disease Type
13.5.2 Spinal Cord Injury Market by Treatment Type
13.6 Spain Spinal Cord Injury Market Overview
13.6.1 Spinal Cord Injury Market by Disease Type
13.6.2 Spinal Cord Injury Market by Treatment Type
13.7 United Kingdom Spinal Cord Injury Market Overview
13.7.1 Spinal Cord Injury Market by Disease Type
13.7.2 Spinal Cord Injury Market by Treatment Type
14 Japan Spinal Cord Injury Market
14.1 Spinal Cord Injury Market Historical Value (2017-2023)
14.2 Spinal Cord Injury Market Forecast Value (2024-2032)
14.2.1 Spinal Cord Injury Market by Disease Type
14.2.2 Spinal Cord Injury Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Novartis AG
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Tenax Therapeutics
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Accure Pharma
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Acorda Therapeutics
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Asterias Biotherapeutics
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 ReNetX Bio.
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 BioArctic AB
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 BioTime, Inc
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 InVivo Therapeutics
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Dr. Reddy's Laboratories Ltd.
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Zydus Cadila
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 AbbVie Inc.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Vertex Pharmaceuticals Inc.
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Pfizer Inc.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Kringle Pharma
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Spinal Cord Injury Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 7215.83 million in 2023, driven by the increased rate of accidents.
The market is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032 and is likely to reach a market value of USD 11574.5 million by 2032.
The market growth is driven by factors such as increased clinical trials and the development of cutting-edge technologies.
The increasing efforts of key players in developing innovative devices for spinal cord injury treatment is a major factor influencing the market growth.
The major regions of the market include United States, EU-4 and the United Kingdom, and Japan. EU-4 can be divided into Germany, France, Italy, and Spain.
The increasing efforts of key players in developing innovative devices for spinal cord injury treatment is a major factor influencing the market growth.
The major regions of the market include United States, EU-4 and the United Kingdom, and Japan. EU-4 can be divided into Germany, France, Italy, and Spain.
The injury types can be segmented into complete spinal cord injury and incomplete spinal cord injury.
The treatment types can be divided into corticosteroid, surgery, and spinal traction.
The end-users include hospitals and clinics, among others.
Key players involved in the market are Novartis AG, Tenax Therapeutics, Accure Pharma, Acorda Therapeutics, Asterias Biotherapeutics, ReNetX Bio., BioArctic AB, BioTime, Inc, InVivo Therapeutics, and Kringle Pharma.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER